Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.63 |
| ▸ | DHODH | Q02127 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077311 | 0.99 | PARP1 (0.65) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5074012 | 0.92 | PARP1 (0.54) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5072040 | 0.92 | PARP1 (0.54) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5072000 | 0.91 | PARP1 (0.53) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5074112 | 0.91 | PARP1 (0.53) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5073313 | 0.89 | PARP1 (0.51) | PARP1DHODHHRH3CHEK2ACHE | |
| SCHEMBL5074086 | 0.87 | PARP1 (0.49) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL6029294 | 0.85 | PARP1 (0.47) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL6029990 | 0.84 | PARP1 (0.60) | PARP1DHODHHRH3CHEK1CHEK2 | |
| SCHEMBL5073297 | 0.80 | TNKS (0.56) | PARP1CHEK1CHEK2PDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7087637-B2 | Substituted indoles which are PARP inhibitors | BASF AG (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885DHODH 1189/4885HRH3 4316/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885DHODH 1189/4885HRH3 4316/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885DHODH 1189/4885HRH3 4316/4885 |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885DHODH 4220/4885HRH3 625/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | PARP1 248/4885DHODH 201/4885HRH3 2262/4885 |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | PARP1, PARP2, PARP12 | PARP1 1/4885DHODH 674/4885HRH3 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.